These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 26021722)

  • 21. Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study.
    Tomita N; Kunieda K; Maeda A; Hamada C; Yamanaka T; Sato T; Yoshida K; Boku N; Nezu R; Yamaguchi S; Mishima H; Sadahiro S; Muro K; Ishiguro M; Sakamoto J; Saji S; Maehara Y
    Br J Cancer; 2019 Apr; 120(7):689-696. PubMed ID: 30833647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer.
    Shi M; Ma T; Xi W; Jiang J; Wu J; Zhou C; Yang C; Zhu Z; Zhang J
    Trials; 2020 Mar; 21(1):249. PubMed ID: 32143730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil and oteracil potassium) for colorectal cancer.
    Kawahara H; Watanabe K; Ushigome T; Noaki R; Kobayashi S; Yanaga K
    Hepatogastroenterology; 2012; 59(113):134-7. PubMed ID: 22251528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy.
    van Erning FN; Janssen-Heijnen ML; Creemers GJ; Pruijt JF; Maas HA; Lemmens VE
    Int J Cancer; 2017 Jan; 140(1):224-233. PubMed ID: 27615021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Schüll B; Schmid K; Kovats E; Schneeweiss B; Lang F; Lenauer A; Depisch D
    J Clin Oncol; 2003 Apr; 21(7):1307-12. PubMed ID: 12663719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Capecitabine].
    Yamaguchi K; Shimamura T; Tada M
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):891-5. PubMed ID: 16835474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine.
    O'Shaughnessy J; Koeppen H; Xiao Y; Lackner MR; Paul D; Stokoe C; Pippen J; Krekow L; Holmes FA; Vukelja S; Lindquist D; Sedlacek S; Rivera R; Brooks R; McIntyre K; Brownstein C; Hoersch S; Blum JL; Jones S
    Clin Cancer Res; 2015 Oct; 21(19):4305-11. PubMed ID: 26041745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged Capecitabine Chemotherapy Following Capecitabine and Oxaliplatin (CAPOX) Regimen Chemotherapy Failed to Improve Survival of Stage III Colorectal Cancer After Radical Resection.
    Xu JL; Tang CW; Feng WM; Bao Y; Chai ZZ
    Med Sci Monit; 2019 Jun; 25():4831-4836. PubMed ID: 31254462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study of the Postoperative Adjuvant Chemotherapy with UFT/LV or Capecitabine for Stage III Colorectal Cancer].
    Maruyama T; Yasuda K; Sako A; Ueda K; Okumura M
    Gan To Kagaku Ryoho; 2016 Jan; 43(1):69-72. PubMed ID: 26809528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
    Komatsu Y; Ishioka C; Shimada K; Yamada Y; Gamoh M; Sato A; Yamaguchi T; Yuki S; Morita S; Takahashi S; Goto R; Kurihara M
    BMC Cancer; 2015 Sep; 15():626. PubMed ID: 26353772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
    Glen H; Cassidy J
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):547-51. PubMed ID: 18402521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
    Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
    J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.
    Yun HR; Kim HC; Yun SH; Lee WY
    Hepatogastroenterology; 2012; 59(120):2466-71. PubMed ID: 23169179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.
    Naeim A; Ward PR; Wang HJ; Dichmann R; Liem AK; Chan D; Patel R; Hu EH; Tchekmedyian NS; Wainberg ZA; Hecht JR
    J Geriatr Oncol; 2013 Oct; 4(4):302-9. PubMed ID: 24472472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laparoscopic or open distal gastrectomy after neoadjuvant chemotherapy for advanced gastric cancer: study protocol for a randomised phase II trial.
    Li Z; Shan F; Ying X; Zhang L; Ren H; Li S; Jia Y; Miao R; Xue K; Li Z; Wang Y; Yan C; Zhang Y; Pang F; Ji J
    BMJ Open; 2018 Aug; 8(8):e021633. PubMed ID: 30099396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous, low-dose capecitabine for patients with recurrent colorectal cancer.
    Romiti A; Onesti CE; Roberto M; Barucca V; Tomao S; D'Antonio C; Durante V; Milano A; Falcone R; Di Rocco R; Righini R; Marchetti P
    Med Oncol; 2015 Mar; 32(3):54. PubMed ID: 25638466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
    Gong J; Liu T; Fan Q; Bai L; Bi F; Qin S; Wang J; Xu N; Cheng Y; Bai Y; Liu W; Wang L; Shen L
    BMC Cancer; 2016 Feb; 16():68. PubMed ID: 26857702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.
    Ducreux M; Malka D; Mendiboure J; Etienne PL; Texereau P; Auby D; Rougier P; Gasmi M; Castaing M; Abbas M; Michel P; Gargot D; Azzedine A; Lombard-Bohas C; Geoffroy P; Denis B; Pignon JP; Bedenne L; Bouché O;
    Lancet Oncol; 2011 Oct; 12(11):1032-44. PubMed ID: 21903473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.